Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test benchmarks for pregnant women could prevent dangerous clots

NCT ID NCT06133621

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 100 pregnant women to determine normal ranges for a blood test called dRVVT, which checks for clotting problems. The goal is to better identify antiphospholipid syndrome, a condition that raises the risk of blood clots and pregnancy complications. By establishing reference values for healthy pregnancies, doctors can more accurately diagnose and manage at-risk women.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better diagnose antiphospholipid syndrome in pregnant women, leading to improved monitoring and treatment to prevent complications like blood clots or pregnancy loss.
What could go wrong
This is a small, completed observational study that only establishes reference values. It does not test a treatment, so it cannot directly improve outcomes without further research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Mar 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Selection by the gynaecologist of pregnant women at the Croix Rousse maternity hospital, who presenting a physiological pregnancy with no history of thromboembolic or autoimmune pathology or vascular disease of pregnancy

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Control group : * patients with normal pregnancies at the HCL. * Affiliation to a social security regime Case group : * Patients followed at the HCL who had an increased dRVVT ratio during pregnancy, investigated as part of the development of VDP during pregnancy. * Affiliation to a social security regime Exclusion Criteria: * History of thromboembolic disease * History of autoimmune disease * History of VDP

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Normal pregnancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome thrombophilia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Normal pregnancy

Contacts and locations

Locations

  • Dr Céline BAZIN

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.